{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T12:23:26Z","timestamp":1771503806923,"version":"3.50.1"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Psychiatry Rep"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1007\/s11920-008-0075-5","type":"journal-article","created":{"date-parts":[[2009,1,7]],"date-time":"2009-01-07T15:11:13Z","timestamp":1231341073000},"page":"465-473","source":"Crossref","is-referenced-by-count":30,"title":["Novel targets for antidepressant therapies"],"prefix":"10.1007","volume":"10","author":[{"given":"Paul E.","family":"Holtzheimer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles B.","family":"Nemeroff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,1,8]]},"reference":[{"key":"75_CR1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/archpsyc.64.3.327","volume":"64","author":"B.W. Dunlop","year":"2007","unstructured":"Dunlop BW, Nemeroff CB: The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007, 64:327\u2013337.","journal-title":"Arch Gen Psychiatry"},{"key":"75_CR2","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1177\/0091270004269560","volume":"44","author":"B. Beer","year":"2004","unstructured":"Beer B, Stark J, Krieter P, et al.: DOV 216,303, a \u201ctriple\u201d reuptake inhibitor: safety, tolerability, and pharmacokinetic profile. J Clin Pharmacol 2004, 44:1360\u20131367.","journal-title":"J Clin Pharmacol"},{"key":"75_CR3","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/archneur.65.5.577","volume":"65","author":"O. Rascol","year":"2008","unstructured":"Rascol O, Poewe W, Lees A, et al.: Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study. Arch Neurol 2008, 65:577\u2013583.","journal-title":"Arch Neurol"},{"key":"75_CR4","doi-asserted-by":"crossref","first-page":"565","DOI":"10.4088\/JCP.v65n0418","volume":"65","author":"A. Bystritsky","year":"2004","unstructured":"Bystritsky A, Ackerman DL, Rosen RM, et al.: Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry 2004, 65:565\u2013568.","journal-title":"J Clin Psychiatry"},{"key":"75_CR5","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.biopsych.2004.11.039","volume":"57","author":"G. Bartzokis","year":"2005","unstructured":"Bartzokis G, Lu PH, Turner J, et al.: Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biol Psychiatry 2005, 57:474\u2013479.","journal-title":"Biol Psychiatry"},{"key":"75_CR6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.4088\/JCP.v65n0212","volume":"65","author":"G.I. Papakostas","year":"2004","unstructured":"Papakostas GI, Petersen TJ, Nierenberg AA, et al.: Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry 2004, 65:217\u2013221.","journal-title":"J Clin Psychiatry"},{"key":"75_CR7","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/JCP.0b013e31816774f9","volume":"28","author":"R.N. Marcus","year":"2008","unstructured":"Marcus RN, McQuade RD, Carson WH, et al.: The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008, 28:156\u2013165.","journal-title":"J Clin Psychopharmacol"},{"key":"75_CR8","doi-asserted-by":"crossref","first-page":"843","DOI":"10.4088\/JCP.v68n0604","volume":"68","author":"R.M. Berman","year":"2007","unstructured":"Berman RM, Marcus RN, Swanink R, et al.: The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, doubleblind, placebo-controlled study. J Clin Psychiatry 2007, 68:843\u2013853.","journal-title":"J Clin Psychiatry"},{"key":"75_CR9","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/da.20130","volume":"23","author":"S.A. Corya","year":"2006","unstructured":"Corya SA, Williamson D, Sanger TM, et al.: A randomized, double-blind comparison of olanzapine\/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 2006, 23:364\u2013372.","journal-title":"Depress Anxiety"},{"key":"75_CR10","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1176\/appi.ajp.162.7.1351","volume":"162","author":"J.R. Calabrese","year":"2005","unstructured":"Calabrese JR, Keck PE Jr, Macfadden W, et al.: A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005, 162:1351\u20131360.","journal-title":"Am J Psychiatry"},{"key":"75_CR11","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/01.jcp.0000248603.76231.b7","volume":"26","author":"M.E. Thase","year":"2006","unstructured":"Thase ME, Macfadden W, Weisler RH, et al.: Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006, 26:600\u2013609.","journal-title":"J Clin Psychopharmacol"},{"key":"75_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hup.817","volume":"22","author":"B.T. Baune","year":"2007","unstructured":"Baune BT, Caliskan S, Todder D: Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression. Hum Psychopharmacol 2007, 22:1\u20139.","journal-title":"Hum Psychopharmacol"},{"key":"75_CR13","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/da.20275","volume":"24","author":"A. McIntyre","year":"2007","unstructured":"McIntyre A, Gendron A, McIntyre A: Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety 2007, 24:487\u2013494.","journal-title":"Depress Anxiety"},{"key":"75_CR14","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.pnpbp.2006.07.002","volume":"31","author":"A. Konstantinidis","year":"2007","unstructured":"Konstantinidis A, Hrubos W, Nirnberger G, et al.: Quetiapine in combination with citalopram in patients with unipolar psychotic depression. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:242\u2013247.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"75_CR15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1185\/030079906X162809","volume":"23","author":"J.P. Doree","year":"2007","unstructured":"Doree JP, Des Rosiers J, Lew V, et al.: Quetiapine augmentation of treatment-resistant depression: a comparison with lithium. Curr Med Res Opin 2007, 23:333\u2013341.","journal-title":"Curr Med Res Opin"},{"key":"75_CR16","doi-asserted-by":"crossref","first-page":"593","DOI":"10.7326\/0003-4819-147-9-200711060-00003","volume":"147","author":"R.A. Mahmoud","year":"2007","unstructured":"Mahmoud RA, Pandina GJ, Turkoz I, et al.: Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med 2007, 147:593\u2013602.","journal-title":"Ann Intern Med"},{"key":"75_CR17","unstructured":"Keitner GI, Garlow SJ, Ryan CE, et al.: A randomized placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat, unipolar, non-psychotic major depression. J Psychiatr Res 2008 Jun 27 (Epub ahead of print)."},{"key":"75_CR18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.biopsych.2004.03.013","volume":"56","author":"C.A. Zarate Jr","year":"2004","unstructured":"Zarate CA Jr, Payne JL, Singh J, et al.: Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004, 56:54\u201360.","journal-title":"Biol Psychiatry"},{"key":"75_CR19","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1176\/appi.ajp.161.3.564","volume":"161","author":"J.F. Goldberg","year":"2004","unstructured":"Goldberg JF, Burdick KE, Endick CJ: Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004, 161:564\u2013566.","journal-title":"Am J Psychiatry"},{"key":"75_CR20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/da.20038","volume":"20","author":"P. Cassano","year":"2004","unstructured":"Cassano P, Lattanzi L, Soldani F, et al.: Pramipexole in treatment-resistant depression: an extended follow-up. Depress Anxiety 2004, 20:131\u2013138.","journal-title":"Depress Anxiety"},{"key":"75_CR21","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1034\/j.1399-5618.2002.01171.x","volume":"4","author":"L. Lattanzi","year":"2002","unstructured":"Lattanzi L, Dell\u2019Osso L, Cassano P, et al.: Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord 2002, 4:307\u2013314.","journal-title":"Bipolar Disord"},{"key":"75_CR22","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/070674370505000612","volume":"50","author":"P. Cassano","year":"2005","unstructured":"Cassano P, Lattanzi L, Fava M, et al.: Ropinirole in treatment-resistant depression: a 16-week pilot study. Can J Psychiatry 2005, 50:357\u2013360.","journal-title":"Can J Psychiatry"},{"key":"75_CR23","first-page":"133","volume-title":"Current and Future Developments in Psychopharmacology","author":"D.A. Gutman","year":"2005","unstructured":"Gutman DA, Owens MJ, Nemeroff CB: Corticotropinreleasing factor receptor and glucocorticoid receptor antagonists: new approaches to antidepressant treatment. In Current and Future Developments in Psychopharmacology. Edited by Den Boer JA, George MS, ter Horst GJ. Amsterdam, The Netherlands: Benecke N.I.; 2005:133\u2013158."},{"key":"75_CR24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0022-3956(00)00016-9","volume":"34","author":"A.W. Zobel","year":"2000","unstructured":"Zobel AW, Nickel T, Kunzel HE, et al.: Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 2000, 34:171\u2013181.","journal-title":"J Psychiatr Res"},{"key":"75_CR25","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1176\/appi.ajp.2008.07071199","volume":"165","author":"B. Binneman","year":"2008","unstructured":"Binneman B, Feltner D, Kolluri S, et al.: A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry 2008, 165:617\u2013620.","journal-title":"Am J Psychiatry"},{"key":"75_CR26","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/sj.npp.1301328","volume":"32","author":"M. Ising","year":"2007","unstructured":"Ising M, Zimmermann US, Kunzel HE, et al.: High-affinity CRF1 receptor antagonist NBI-34041: preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response. Neuropsychopharmacology 2007, 32:1941\u20131949.","journal-title":"Neuropsychopharmacology"},{"key":"75_CR27","first-page":"209","volume":"18","author":"B.E. Murphy","year":"1993","unstructured":"Murphy BE, Filipini D, Ghadirian AM: Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486. J Psychiatry Neurosci 1993, 18:209\u2013213.","journal-title":"J Psychiatry Neurosci"},{"key":"75_CR28","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/00004714-200110000-00009","volume":"21","author":"J.K. Belanoff","year":"2001","unstructured":"Belanoff JK, Flores BH, Kalezhan M, et al.: Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol 2001, 21:516\u2013521.","journal-title":"J Clin Psychopharmacol"},{"key":"75_CR29","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0006-3223(02)01432-4","volume":"52","author":"J.K. Belanoff","year":"2002","unstructured":"Belanoff JK, Rothschild AJ, Cassidy F, et al.: An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry 2002, 52:386\u2013392.","journal-title":"Biol Psychiatry"},{"key":"75_CR30","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1139\/y95-122","volume":"73","author":"J. Culman","year":"1995","unstructured":"Culman J, Unger T: Central tachykinins: mediators of defence reaction and stress reactions. Can J Physiol Pharmacol 1995, 73:885\u2013891.","journal-title":"Can J Physiol Pharmacol"},{"key":"75_CR31","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1126\/science.281.5383.1640","volume":"281","author":"M.S. Kramer","year":"1998","unstructured":"Kramer MS, Cutler N, Feighner J, et al.: Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998, 281:1640\u20131645.","journal-title":"Science"},{"key":"75_CR32","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1176\/ajp.2006.163.4.637","volume":"163","author":"T.D. Geracioti Jr","year":"2006","unstructured":"Geracioti TD Jr, Carpenter L, Owens MJ, et al.: Elevated cerebrospinal fluid substance P concentrations in post-traumatic stress disorder and major depression. Am J Psychiatry 2006, 163:637\u2013643.","journal-title":"Am J Psychiatry"},{"key":"75_CR33","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0006-3223(02)01544-5","volume":"53","author":"B. Bondy","year":"2003","unstructured":"Bondy B, Baghai TC, Minov C, et al.: Substance P serum levels are increased in major depression: preliminary results. Biol Psychiatry 2003, 53:538\u2013542.","journal-title":"Biol Psychiatry"},{"key":"75_CR34","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.biopsych.2005.07.013","volume":"59","author":"M. Keller","year":"2006","unstructured":"Keller M, Montgomery S, Ball W, et al.: Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry 2006, 59:216\u2013223.","journal-title":"Biol Psychiatry"},{"key":"75_CR35","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/sj.npp.1300260","volume":"29","author":"M.S. Kramer","year":"2004","unstructured":"Kramer MS, Winokur A, Kelsey J, et al.: Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 2004, 29:385\u2013392.","journal-title":"Neuropsychopharmacology"},{"key":"75_CR36","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/00023210-200519040-00001","volume":"19","author":"I. Herpfer","year":"2005","unstructured":"Herpfer I, Lieb K: Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential. CNS Drugs 2005, 19:275\u2013293.","journal-title":"CNS Drugs"},{"key":"75_CR37","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.biopsych.2005.03.029","volume":"58","author":"T. Furmark","year":"2005","unstructured":"Furmark T, Appel L, Michelgard A, et al.: Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry 2005, 58:132\u2013142.","journal-title":"Biol Psychiatry"},{"key":"75_CR38","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.bbr.2006.05.011","volume":"172","author":"F. Chenu","year":"2006","unstructured":"Chenu F, Guiard BP, Bourin M, et al.: Antidepressant-like activity of selective serotonin reuptake inhibitors combined with a NK1 receptor antagonist in the mouse forced swimming test. Behav Brain Res 2006, 172:256\u2013263.","journal-title":"Behav Brain Res"},{"key":"75_CR39","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1196\/annals.1300.016","volume":"1003","author":"I.A. Paul","year":"2003","unstructured":"Paul IA, Skolnick P: Glutamate and depression: clinical and preclinical studies. Ann N Y Acad Sci 2003, 1003:250\u2013272.","journal-title":"Ann N Y Acad Sci"},{"key":"75_CR40","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0006-3223(00)00971-9","volume":"48","author":"R.M. Sapolsky","year":"2000","unstructured":"Sapolsky RM: The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol Psychiatry 2000, 48:755\u2013765.","journal-title":"Biol Psychiatry"},{"key":"75_CR41","first-page":"179","volume":"56","author":"Z. Rogoz","year":"2004","unstructured":"Rogoz Z, Skuza G, Kusmider M, et al.: Synergistic effect of imipramine and amantadine in the forced swimming test in rats. Behavioral and pharmacokinetic studies. Pol J Pharmacol 2004, 56:179\u2013185.","journal-title":"Pol J Pharmacol"},{"key":"75_CR42","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00004850-200303000-00005","volume":"18","author":"R. Stryjer","year":"2003","unstructured":"Stryjer R, Strous RD, Shaked G, et al.: Amantadine as augmentation therapy in the management of treatment-resistant depression. Int Clin Psychopharmacol 2003, 18:93\u201396.","journal-title":"Int Clin Psychopharmacol"},{"key":"75_CR43","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.pbb.2005.06.015","volume":"81","author":"A. Palucha","year":"2005","unstructured":"Palucha A, Branski P, Szewczyk B, et al.: Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. Pharmacol Biochem Behav 2005, 81:901\u2013906.","journal-title":"Pharmacol Biochem Behav"},{"key":"75_CR44","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1176\/appi.ajp.162.7.1385","volume":"162","author":"R. Ostroff","year":"2005","unstructured":"Ostroff R, Gonzales M, Sanacora G: Antidepressant effect of ketamine during ECT. Am J Psychiatry 2005, 162:1385\u20131386.","journal-title":"Am J Psychiatry"},{"key":"75_CR45","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"C.A. Zarate Jr","year":"2006","unstructured":"Zarate CA Jr, Singh JB, Carlson PJ, et al.: A randomized trial of an N-methyl-D-aspartate antagonist in treatmentresistant major depression. Arch Gen Psychiatry 2006, 63:856\u2013864.","journal-title":"Arch Gen Psychiatry"},{"key":"75_CR46","first-page":"1","volume":"10","author":"M. Liebrenz","year":"2007","unstructured":"Liebrenz M, Stohler R, Borgeat A: Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression. World J Biol Psychiatry 2007, 10:1\u20134.","journal-title":"World J Biol Psychiatry"},{"key":"75_CR47","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1176\/appi.ajp.163.1.153","volume":"163","author":"C.A. Zarate Jr","year":"2006","unstructured":"Zarate CA Jr, Singh JB, Quiroz JA, et al.: A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 2006, 163:153\u2013155.","journal-title":"Am J Psychiatry"},{"key":"75_CR48","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1176\/appi.ajp.161.1.171","volume":"161","author":"C.A. Zarate Jr","year":"2004","unstructured":"Zarate CA Jr, Payne JL, Quiroz J, et al.: An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 2004, 161:171\u2013174.","journal-title":"Am J Psychiatry"},{"key":"75_CR49","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.biopsych.2004.11.023","volume":"57","author":"C.A. Zarate Jr","year":"2005","unstructured":"Zarate CA Jr, Quiroz JA, Singh JB, et al.: An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 2005, 57:430\u2013432.","journal-title":"Biol Psychiatry"},{"key":"75_CR50","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.biopsych.2006.08.037","volume":"61","author":"G. Sanacora","year":"2007","unstructured":"Sanacora G, Kendell SF, Levin Y, et al.: Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 2007, 61:822\u2013825.","journal-title":"Biol Psychiatry"},{"key":"75_CR51","first-page":"259","volume":"17","author":"M.I. Levy","year":"1982","unstructured":"Levy MI, DeNigris Y, Davis KL: Rapid antidepressant activity of melanocyte-inhibiting factor: a clinical trial. Biol Psychiatry 1982, 17:259\u2013263.","journal-title":"Biol Psychiatry"},{"key":"75_CR52","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1017\/S1461145705006139","volume":"9","author":"S.A. Montgomery","year":"2006","unstructured":"Montgomery SA, Feighner JP, Sverdlov L, et al.: Efficacy and safety of 30 mg\/d and 45 mg\/d nemifitide compared to placebo in major depressive disorder. Int J Neuropsychopharmacol 2006, 9:517\u2013528.","journal-title":"Int J Neuropsychopharmacol"},{"key":"75_CR53","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1176\/ajp.2006.163.6.969","volume":"163","author":"G. Parker","year":"2006","unstructured":"Parker G, Gibson NA, Brotchie H, et al.: Omega-3 fatty acids and mood disorders. Am J Psychiatry 2006, 163:969\u2013978.","journal-title":"Am J Psychiatry"},{"key":"75_CR54","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1176\/appi.ajp.159.3.477","volume":"159","author":"B. Nemets","year":"2002","unstructured":"Nemets B, Stahl Z, Belmaker RH: Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 2002, 159:477\u2013479.","journal-title":"Am J Psychiatry"},{"key":"75_CR55","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/archpsyc.56.5.407","volume":"56","author":"A.L. Stoll","year":"1999","unstructured":"Stoll AL, Severus WE, Freeman MP, et al.: Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebocontrolled trial. Arch Gen Psychiatry 1999, 56:407\u2013412.","journal-title":"Arch Gen Psychiatry"},{"key":"75_CR56","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.biopsych.2006.03.056","volume":"60","author":"P.E. Keck Jr","year":"2006","unstructured":"Keck PE Jr, Mintz J, McElroy SL, et al.: Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry 2006, 60:1020\u20131022.","journal-title":"Biol Psychiatry"},{"key":"75_CR57","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.4088\/JCP.v68n0712","volume":"68","author":"P.Y. Lin","year":"2007","unstructured":"Lin PY, Su KP: A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry 2007, 68:1056\u20131061.","journal-title":"J Clin Psychiatry"},{"key":"75_CR58","doi-asserted-by":"crossref","first-page":"644","DOI":"10.4088\/JCP.v69n0418","volume":"69","author":"K.P. Su","year":"2008","unstructured":"Su KP, Huang SY, Chiu TH, et al.: Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008, 69:644\u2013651.","journal-title":"J Clin Psychiatry"},{"key":"75_CR59","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/00048670701827267","volume":"42","author":"A.M. Rees","year":"2008","unstructured":"Rees AM, Austin MP, Parker GB: Omega-3 fatty acids as a treatment for perinatal depression: randomized doubleblind placebo-controlled trial. Aust N Z J Psychiatry 2008, 42:199\u2013205.","journal-title":"Aust N Z J Psychiatry"},{"key":"75_CR60","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0165-1781(97)00128-5","volume":"77","author":"A.J. Lewy","year":"1998","unstructured":"Lewy AJ, Bauer VK, Cutler NL, et al.: Melatonin treatment of winter depression: a pilot study. Psychiatry Res 1998, 77:57\u201361.","journal-title":"Psychiatry Res"},{"key":"75_CR61","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1176\/ajp.155.8.1119","volume":"155","author":"O.T. Dolberg","year":"1998","unstructured":"Dolberg OT, Hirschmann S, Grunhaus L: Melatonin for the treatment of sleep disturbances in major depressive disorder. Am J Psychiatry 1998, 155:1119\u20131121.","journal-title":"Am J Psychiatry"},{"key":"75_CR62","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00004850-200209000-00004","volume":"17","author":"H. Loo","year":"2002","unstructured":"Loo H, Hale A, D\u2019Haenen H: Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002, 17:239\u2013247.","journal-title":"Int Clin Psychopharmacol"},{"key":"75_CR63","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.euroneuro.2005.09.002","volume":"16","author":"S.H. Kennedy","year":"2006","unstructured":"Kennedy SH, Emsley R: Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006, 16:93\u2013100.","journal-title":"Eur Neuropsychopharmacol"},{"key":"75_CR64","first-page":"661","volume":"10","author":"J.P. Olie","year":"2007","unstructured":"Olie JP, Kasper S: Efficacy of agomelatine, a MT1\/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007, 10:661\u2013673.","journal-title":"Int J Neuropsychopharmacol"},{"key":"75_CR65","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1399-5618.2007.00507.x","volume":"9","author":"J.R. Calabrese","year":"2007","unstructured":"Calabrese JR, Guelfi JD, Perdrizet-Chevallier C: Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord 2007, 9:628\u2013635.","journal-title":"Bipolar Disord"},{"key":"75_CR66","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1001\/archpsyc.63.12.1337","volume":"63","author":"C.H. Kellner","year":"2006","unstructured":"Kellner CH, Knapp RG, Petrides G, et al.: Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). Arch Gen Psychiatry 2006, 63:1337\u20131344.","journal-title":"Arch Gen Psychiatry"},{"key":"75_CR67","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S1474-4422(02)00220-X","volume":"1","author":"E. Ben-Menachem","year":"2002","unstructured":"Ben-Menachem E: Vagus-nerve stimulation for the treatment of epilepsy. Lancet Neurol 2002, 1:477\u2013482.","journal-title":"Lancet Neurol"},{"key":"75_CR68","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0893-133X(01)00271-8","volume":"25","author":"H.A. Sackeim","year":"2001","unstructured":"Sackeim HA, Rush AJ, George MS, et al.: Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology 2001, 25:713\u2013728.","journal-title":"Neuropsychopharmacology"},{"key":"75_CR69","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.4088\/JCP.v66n0902","volume":"66","author":"Z. Nahas","year":"2005","unstructured":"Nahas Z, Marangell LB, Husain MM, et al.: Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry 2005, 66:1097\u20131104.","journal-title":"J Clin Psychiatry"},{"key":"75_CR70","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.biopsych.2005.05.025","volume":"58","author":"A.J. Rush","year":"2005","unstructured":"Rush AJ, Marangell LB, Sackeim HA, et al.: Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005, 58:347\u2013354.","journal-title":"Biol Psychiatry"},{"key":"75_CR71","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.biopsych.2005.05.024","volume":"58","author":"A.J. Rush","year":"2005","unstructured":"Rush AJ, Sackeim HA, Marangell LB, et al.: Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry 2005, 58:355\u2013363.","journal-title":"Biol Psychiatry"},{"key":"75_CR72","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.biopsych.2005.07.028","volume":"58","author":"M.S. George","year":"2005","unstructured":"George MS, Rush AJ, Marangell LB, et al.: A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry 2005, 58:364\u2013373.","journal-title":"Biol Psychiatry"},{"key":"75_CR73","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1017\/S1461145706007425","volume":"10","author":"H.A. Sackeim","year":"2007","unstructured":"Sackeim HA, Brannan SK, Rush AJ, et al.: Durability of antidepressant response to vagus nerve stimulation (VNS). Int J Neuropsychopharmacol 2007, 10:817\u2013826.","journal-title":"Int J Neuropsychopharmacol"},{"key":"75_CR74","doi-asserted-by":"crossref","first-page":"688","DOI":"10.4088\/JCP.v67n0501","volume":"67","author":"D.L. Dunner","year":"2006","unstructured":"Dunner DL, Rush AJ, Russell JM, et al.: Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J Clin Psychiatry 2006, 67:688\u2013695.","journal-title":"J Clin Psychiatry"},{"key":"75_CR75","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1017\/S1461145702002791","volume":"5","author":"T. Burt","year":"2002","unstructured":"Burt T, Lisanby SH, Sackeim HA: Neuropsychiatric applications of transcranial magnetic stimulation: a metaanalysis. Int J Neuropsychopharmacol 2002, 5:73\u2013103.","journal-title":"Int J Neuropsychopharmacol"},{"key":"75_CR76","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/archpsyc.56.4.315","volume":"56","author":"E. Klein","year":"1999","unstructured":"Klein E, Kreinin I, Chistyakov A, et al.: Therapeutic efficacy of right prefrontal slow repetitive transcranial magnetic stimulation in major depression: a double-blind controlled study. Arch Gen Psychiatry 1999, 56:315\u2013320.","journal-title":"Arch Gen Psychiatry"},{"key":"75_CR77","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1001\/archpsyc.60.9.1002","volume":"60","author":"P.B. Fitzgerald","year":"2003","unstructured":"Fitzgerald PB, Brown TL, Marston NA, et al.: Transcranial magnetic stimulation in the treatment of depression: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 2003, 60:1002\u20131008.","journal-title":"Arch Gen Psychiatry"},{"key":"75_CR78","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1176\/appi.ajp.160.5.835","volume":"160","author":"A.A. Gershon","year":"2003","unstructured":"Gershon AA, Dannon PN, Grunhaus L: Transcranial magnetic stimulation in the treatment of depression. Am J Psychiatry 2003, 160:835\u2013845.","journal-title":"Am J Psychiatry"},{"key":"75_CR79","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.biopsych.2005.07.003","volume":"59","author":"D.H. Avery","year":"2006","unstructured":"Avery DH, Holtzheimer PE 3rd, Fawaz W, et al.: A controlled study of repetitive transcranial magnetic stimulation in medication-resistant major depression. Biol Psychiatry 2006, 59:187\u2013194.","journal-title":"Biol Psychiatry"},{"key":"75_CR80","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.biopsych.2007.01.018","volume":"62","author":"J.P. O\u2019Reardon","year":"2007","unstructured":"O\u2019Reardon JP, Solvason HB, Janicak PG, et al.: Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry 2007, 62:1208\u20131216.","journal-title":"Biol Psychiatry"},{"key":"75_CR81","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/sj.npp.1300229","volume":"28","author":"S.H. Lisanby","year":"2003","unstructured":"Lisanby SH, Luber B, Schlaepfer TE, et al.: Safety and feasibility of magnetic seizure therapy (MST) in major depression: randomized within-subject comparison with electroconvulsive therapy. Neuropsychopharmacology 2003, 28:1852\u20131865.","journal-title":"Neuropsychopharmacology"},{"key":"75_CR82","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1038\/sj.npp.1300293","volume":"28","author":"M. Kosel","year":"2003","unstructured":"Kosel M, Frick C, Lisanby SH, et al.: Magnetic seizure therapy improves mood in refractory major depression. Neuropsychopharmacology 2003, 28:2045\u20132048.","journal-title":"Neuropsychopharmacology"},{"key":"75_CR83","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1213\/01.ane.0000221182.71648.a3","volume":"103","author":"P.F. White","year":"2006","unstructured":"White PF, Amos Q, Zhang Y, et al.: Anesthetic considerations for magnetic seizure therapy: a novel therapy for severe depression. Anesth Analg 2006, 103:76\u201380.","journal-title":"Anesth Analg"},{"key":"75_CR84","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1017\/S1461145707007833","volume":"11","author":"P.S. Boggio","year":"2008","unstructured":"Boggio PS, Rigonatti SP, Ribeiro RB, et al.: A randomized, double-blind clinical trial on the efficacy of cortical direct current stimulation for the treatment of major depression. Int J Neuropsychopharmacol 2008, 11:249\u2013254.","journal-title":"Int J Neuropsychopharmacol"},{"key":"75_CR85","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.neuron.2005.02.014","volume":"45","author":"H.S. Mayberg","year":"2005","unstructured":"Mayberg HS, Lozano AM, Voon V, et al.: Deep brain stimulation for treatment-resistant depression. Neuron 2005, 45:651\u2013660.","journal-title":"Neuron"},{"key":"75_CR86","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.biopsych.2008.05.034","volume":"64","author":"A.M. Lozano","year":"2008","unstructured":"Lozano AM, Mayberg HS, Giacobbe P, et al.: Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. Biol Psychiatry 2008, 64:461\u2013467.","journal-title":"Biol Psychiatry"},{"key":"75_CR87","first-page":"59","volume":"12","author":"B.D. Greenberg","year":"2005","unstructured":"Greenberg BD, Nahas Z, Carpenter LL: Current status of deep brain stimulation. Prim Psychiatry 2005, 12:59\u201364.","journal-title":"Prim Psychiatry"},{"key":"75_CR88","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/sj.npp.1301408","volume":"33","author":"T.E. Schlaepfer","year":"2008","unstructured":"Schlaepfer TE, Cohen MX, Frick C, et al.: Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. Neuropsychopharmacology 2008, 33:368\u2013377.","journal-title":"Neuropsychopharmacology"},{"key":"75_CR89","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1227\/01.NEU.0000170434.44335.19","volume":"57","author":"F. Jimenez","year":"2005","unstructured":"Jimenez F, Velasco F, Salin-Pascual R, et al.: A patient with a resistant major depression disorder treated with deep brain stimulation in the inferior thalamic peduncle. Neurosurgery 2005, 57:585\u2013593; discussion 585\u2013593.","journal-title":"Neurosurgery"},{"key":"75_CR90","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.mehy.2007.03.021","volume":"69","author":"A. Sartorius","year":"2007","unstructured":"Sartorius A, Henn FA: Deep brain stimulation of the lateral habenula in treatment resistant major depression. Med Hypotheses 2007, 69:1305\u20131308.","journal-title":"Med Hypotheses"},{"key":"75_CR91","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1038\/sj.npp.1301165","volume":"31","author":"B.D. Greenberg","year":"2006","unstructured":"Greenberg BD, Malone DA, Friehs GM, et al.: Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. Neuropsychopharmacology 2006, 31:2384\u20132393.","journal-title":"Neuropsychopharmacology"}],"container-title":["Current Psychiatry Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-008-0075-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11920-008-0075-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-008-0075-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T20:27:32Z","timestamp":1709929652000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11920-008-0075-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":91,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["75"],"URL":"https:\/\/doi.org\/10.1007\/s11920-008-0075-5","relation":{},"ISSN":["1523-3812","1535-1645"],"issn-type":[{"value":"1523-3812","type":"print"},{"value":"1535-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}